Skip to content
Calculator
Analysis

CagriSema's FDA Decision: What It Is, What the Trials Showed, and What to Watch

Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board

A digital glass bathroom scale with a blue tape measure resting on it
Photo by Pixabay on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • CagriSema is two drugs in one weekly injection: cagrilintide, an amylin analogue, and semaglutide, the GLP-1 agonist in Wegovy. Novo Nordisk filed it with FDA in December 2025 for weight management 3.
  • In REDEFINE 1, 3,417 adults without diabetes lost 20.4% of body weight at 68 weeks against 3.0% on placebo. That is the treatment-policy figure NEJM reports; the 22.7% in Novo Nordisk's December 2024 announcement is a different estimand, which is why two numbers circulate for one trial 6 8.
  • In the same trial, semaglutide alone was one of the comparator arms, and in a separate programme CagriSema beat semaglutide 2.4 mg on blood sugar by 0.16 percentage points, which is significant and small at once 2.
  • In REDEFINE 4, the head-to-head against tirzepatide 15 mg, Novo Nordisk reported in February 2026 that CagriSema lost 20.2% against 23.6% and did not show non-inferiority; the result is a company release, not yet a peer-reviewed paper 4.

What CagriSema is

CagriSema is a fixed combination of two peptides given as one weekly injection under the skin. Semaglutide is the GLP-1 receptor agonist sold as Wegovy for weight management and Ozempic for type 2 diabetes. Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety 1; it acts on amylin receptors rather than GLP-1 receptors.

The logic of combining them is that the two drugs have complementary effects on blood sugar and body weight, as the REIMAGINE 2 investigators put it 2. Novo Nordisk submitted the application to FDA in December 2025, based on REDEFINE 1 and REDEFINE 2, and in February 2026 said it expected a decision by late 2026 3 4. FDA's list of 2026 novel drug approvals shows no CagriSema approval as of October 27, 2026 5, and the application concerns weight management 3.

Why add an amylin analogue to a GLP-1 drug

Amylin is a pancreatic hormone that induces satiety, and cagrilintide is a long-acting analogue of it given once a week 1. It has been tested on its own: in a 26-week phase 2 trial in 706 people with overweight or obesity given cagrilintide, weight fell 6.0% to 10.8% across doses against 3.0% on placebo, and the top dose, 4.5 mg, beat liraglutide 3.0 mg (10.8% against 9.0%); gastrointestinal adverse events affected 41% to 63% against 32% on placebo 1. REDEFINE 1 also had cagrilintide-alone and semaglutide-alone arms 6.

The practical consequence is that CagriSema is not a reformulated semaglutide. It is two active drugs, with two mechanisms arriving together.

REDEFINE 1: the trial the application rests on

REDEFINE 1 was a 68-week phase 3a trial in 3,417 adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication. Participants were randomised to CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, each with lifestyle intervention 6.

Mean body weight fell 20.4% on CagriSema against 3.0% on placebo, a difference of 17.3 percentage points. More participants reached every weight-loss threshold the trial measured, including reductions of 20%, 25% and 30% or more. Gastrointestinal adverse events affected 79.6% of the CagriSema group against 39.9% on placebo, and were mostly transient and mild to moderate 6.

A separate analysis of the same trial looked at blood pressure. Systolic pressure fell 10.9 mm Hg on CagriSema against 2.8 on placebo, 63.0% of the CagriSema group reached blood-pressure targets against 32.0%, and among participants taking blood-pressure medicines, 39.6% reduced or stopped them against 18.8% on placebo 7.

Why two different numbers circulate

When REDEFINE 1 first reported, in December 2024, Novo Nordisk's announcement gave 22.7% for people who adhered to treatment and 20.4% under the treatment-policy estimand 8. The published paper leads with 20.4% 6. Both are real, and the difference is not a correction. It is a choice of estimand, the formal definition of what a trial is measuring.

The treatment-policy estimand asks what happened to everyone randomised, whether or not they kept taking the drug or added a rescue treatment. That is the intention-to-treat principle, and it answers: what does prescribing this do? The trial-product estimand asks what would happen if everyone adhered to treatment 1, which gives a larger number when some people stop.

Neither is dishonest, but they answer different questions, and a comparison between two drugs is only fair if both are quoted on the same basis. When a figure for CagriSema is set against one for another drug, the first thing worth checking is whether the two came from the same kind of estimand.

REDEFINE 2: the same combination in type 2 diabetes

REDEFINE 2 ran the combination in 1,206 adults with type 2 diabetes and a BMI of 27 or more (overweight or obesity), randomised 3:1 against placebo across 12 countries for 68 weeks. Weight fell 13.7% against 3.4% on placebo, a difference of 10.4 percentage points 9.

On blood sugar the result was large: 73.5% of the CagriSema group reached a glycated haemoglobin of 6.5% or less, against 15.9% on placebo. Gastrointestinal adverse events were reported by 72.5% against 34.4% 9.

REIMAGINE: what happened against semaglutide itself

The REIMAGINE programme tested the combination in type 2 diabetes and published in 2026. Its largest trial, REIMAGINE 2, randomised 2,713 people across six arms for 68 weeks and compared the combination directly with semaglutide 2.4 mg. Glycated haemoglobin fell 1.91 percentage points on the combination against 1.75 on semaglutide: a difference of 0.16 points, statistically significant at p=0.0035 2.

That margin is worth sitting with. It is the cleanest published comparison between CagriSema and one of its own two components, and on blood sugar in that population the gap is narrow 2.

The two smaller trials were against placebo. REIMAGINE 1, in 189 people managing diabetes with diet and exercise, cut glycated haemoglobin 1.8 points and weight 13.8% over 40 weeks at the 2.4 mg dose of each, against 0.1 points and 1.4% on placebo 10. REIMAGINE 3 added the combination to basal insulin in 274 people: glycated haemoglobin fell 2.33 points against 0.66 on placebo, with weight reductions of 10 to 12% and no severe hypoglycaemia reported 11.

What the trials found on safety

The dominant signal across both REDEFINE trials is gastrointestinal. In REDEFINE 1, 79.6% of the CagriSema group reported a gastrointestinal adverse event against 39.9% on placebo; in REDEFINE 2 the figures were 72.5% and 34.4% 6 9. Nausea, vomiting, diarrhoea, constipation and abdominal pain were the events recorded, mostly transient and mild to moderate in severity 6. These are rates in monitored trials.

The REIMAGINE trials add the diabetes picture. In REIMAGINE 3, where the combination was added to basal insulin, no severe hypoglycaemia was reported 11. One death occurred in that trial, in the lower-dose group, due to malignancy and not related to treatment 11.

What the published trials do not yet show is long-term use. REDEFINE 1 ran 68 weeks and REDEFINE 4 84 weeks 6 4, and none of the published trials reports what happens after the combination is stopped; our article on stopping a GLP-1 covers what happened when semaglutide was withdrawn.

CagriSema against tirzepatide: what is actually known

The comparison most people want is against tirzepatide, sold as Zepbound for weight management. REDEFINE 4 made it: an open-label phase 3 trial in 809 people with obesity and at least one complication, CagriSema 2.4/2.4 mg against tirzepatide 15 mg for 84 weeks. Novo Nordisk announced on February 23, 2026 that weight fell 20.2% on CagriSema against 23.6% on tirzepatide under the treatment-regimen estimand (23.0% against 25.5% if everyone had adhered), and that the trial did not achieve its primary endpoint, non-inferiority to tirzepatide 4. That is a company's topline release; we found no peer-reviewed paper in PubMed as of October 27, 2026, and the registry lists the trial as completed (ClinicalTrials.gov NCT06131437) 4. A 2026 network meta-analysis of 25 placebo-controlled trials, an indirect comparison, ranked tirzepatide 15 mg (-17.97% against placebo) and CagriSema (-17.84%) close together and called for head-to-head trials 12.

Before REDEFINE 4, all anyone could do was set each drug's own trial against its own placebo, and that is a weaker thing than a comparison. Semaglutide 2.4 mg alone produced 14.9% weight loss against 2.4% on placebo in its own 68-week trial 13, and CagriSema produced 20.4% against 3.0% in REDEFINE 1, but those are two trials, not one. Different trials enrol different people under different protocols, and weight-loss percentages from separate studies are not interchangeable. The estimand problem above applies with full force here: two numbers from two trials may not even be measuring the same quantity.

When REDEFINE 4 is published in a journal, this article will be updated from the paper.

What is sold as CagriSema online

Anything sold as CagriSema as of October 27, 2026 is not the product FDA is reviewing: the application covers a specific fixed-dose combination made to pharmaceutical standards, and nothing sold as a research chemical has been through that.

FDA says cagrilintide cannot be used in compounding under federal law, because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition, and that it has warned companies selling unapproved GLP-1 drugs falsely labelled 'for research purposes' or 'not for human consumption' 14. The practical point for a reader is narrower than the legal one: the trial results on this page describe a manufactured combination at defined doses, given weekly in a monitored trial for 68 weeks, with gastrointestinal adverse events in four out of five participants 6. None of that transfers to a vial of unknown content.

Our guide to what research-use-only actually means covers the labelling, and the regulatory tracker follows the enforcement.

What to watch in the decision

Three things are worth following. The first is the indication FDA grants, if it grants one: the population in REDEFINE 1 was adults with obesity, or overweight with a complication 6.

The second is tolerability in the label. Nearly 80% of the CagriSema group in REDEFINE 1 had a gastrointestinal adverse event, against 39.9% on placebo 6.

The third is the diabetes question. The REDEFINE and REIMAGINE programmes cover both weight and blood sugar, but the application Novo Nordisk announced is for weight management 3.

Our regulatory tracker follows FDA decisions on peptide drugs, and the CagriSema encyclopedia entry carries the trial list and the current status.

Frequently asked questions

Is CagriSema approved?

No. Novo Nordisk filed the application with FDA in December 2025, and FDA's list of 2026 novel drug approvals showed no CagriSema approval as of October 27, 2026.

How much weight did people lose on CagriSema?

In REDEFINE 1, 20.4% of body weight at 68 weeks against 3.0% on placebo, in 3,417 adults without diabetes. A higher figure, 22.7%, also circulates from the company's 2024 announcement; it estimates the effect if everyone had adhered to treatment.

Is CagriSema better than Zepbound?

In REDEFINE 4, an open-label 84-week trial, Novo Nordisk reported 20.2% weight loss on CagriSema against 23.6% on tirzepatide 15 mg (Zepbound's drug), and CagriSema did not show non-inferiority. The result is a February 2026 company release, not yet a peer-reviewed paper.

What is cagrilintide?

A long-acting analogue of amylin, a pancreatic hormone that induces satiety. It acts on amylin receptors rather than GLP-1 receptors, and alone it cut weight 6.0% to 10.8% in a 26-week phase 2 trial.

Did CagriSema beat semaglutide on its own?

On weight, semaglutide alone was a comparator arm in REDEFINE 1. On blood sugar, REIMAGINE 2 found CagriSema beat semaglutide 2.4 mg by 0.16 percentage points of glycated haemoglobin, a result that is statistically significant and clinically small.

Sources

  1. Lau, D. C. W. et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, 398(10317), 2160-2172. PMID: 34798060
  2. Buse, J. B. et al. (2026). Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol. ClinicalTrials.gov NCT06065540. PMID: 42251859
  3. Novo Nordisk. Company announcement: filing of CagriSema with the US Food and Drug Administration for weight management, December 2025 (the February 23, 2026 Form 6-K repeats the December 2025 submission, based on REDEFINE 1 and 2, with a decision expected by late 2026). Cited without a link; manufacturers are not linked from this site.
  4. Novo Nordisk. Company announcement, February 23, 2026 (Form 6-K filed with the US SEC): REDEFINE 4, open-label phase 3, 809 people with obesity, CagriSema 2.4/2.4 mg vs tirzepatide 15 mg for 84 weeks; 23.0% vs 25.5% (efficacy estimand) and 20.2% vs 23.6% (treatment-regimen estimand); primary endpoint of non-inferiority not achieved. A company release of topline results, not peer-reviewed; read October 27, 2026; cited without a link. Registry: ClinicalTrials.gov NCT06131437 (completed; primary completion December 8, 2025).
  5. Grey Peptides dataset row for CagriSema: FDA's list of 2026 novel drug approvals (content current as of October 20, 2026; read October 27, 2026) lists no CagriSema approval.
  6. Garvey, W. T. et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. REDEFINE 1, ClinicalTrials.gov NCT05567796. PMID: 40544433
  7. Verma, S. et al. (2026). CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. PMID: 41328546
  8. Novo Nordisk. Company announcement, December 20, 2024 (Form 6-K filed with the US SEC): REDEFINE 1 topline, 22.7% weight loss at 68 weeks 'if all people adhered to treatment' (trial product estimand) and 20.4% with the treatment policy estimand. A company release, read October 27, 2026; cited without a link.
  9. Davies, M. J. et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. REDEFINE 2, ClinicalTrials.gov NCT05394519. PMID: 40544432
  10. Aroda, V. R. et al. (2026). Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol. ClinicalTrials.gov NCT06323174. PMID: 42251860
  11. Rosenstock, J. et al. (2026). Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3). Lancet. ClinicalTrials.gov NCT06323161. PMID: 42251856
  12. Hamarsheh, S. et al. (2026). Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinol Diabetes Metab, 9(4), e70248. PMID: 42207966
  13. Wilding, J. P. H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11), 989-1002. STEP 1. PMID: 33567185
  14. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (cagrilintide cannot be used in compounding; warnings to companies selling products labelled 'for research purposes'). Content current as of October 1, 2026; read October 27, 2026. FDA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. CagriSema is not FDA-approved; weight and diabetes treatment is a decision for a person and their prescriber.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead